wafaa Mohamed elzefzafy

EDUCATION

MD Tropical Medicine
Master Tropical Medicine

RESEARCH INTERESTS

GIT
Hepatology
Infectious disease

Scopus Publications

Seroprevalence and epidemiological characteristics of HDV infection among HBV patients in the Nile Delta, Egypt
Wafaa Elzefzafy, Reham Soliman, Layla Saleh, Safyia Mahmoud, Nahed A Makhlouf, Gamal Shiha, and Samy Zaky
Wiley
The epidemiology of HDV infection worldwide is obscure. Mapping the epidemiology of the infection is highly required, so, we aimed to estimate the prevalence of hepatitis D virus infection among chronic hepatitis B patients and the epidemiological characteristics in the Nile delta in Egypt. This was a prospective observational cross‐sectional study including consecutive chronic hepatitis B patients in the out‐patient clinics at the Egyptian Liver Research Institute and Hospital (ELRIAH) and its satellites in the Nile Delta from January 2016 until August 2018. They were recruited from patients enrolled in Educate, Test and Treat program, which was implemented in 73 Egyptian Villages. Subjects were tested by using HBsAg serological rapid diagnostic tests (RDTs), and then HBV DNA by PCR was done in HBsAg‐positive cases. HDV IgG antibody testing and confirmatory HDV RNA PCR were done. Complete liver functions, abdominal ultrasonography and FibroScan were also performed. The prevalence of HDV was 3.4% using anti‐delta antibody (22/631), and only 8 were positive for HDV RNA (8/22, 36.4%). Overall HDV prevalence using PCR was 8/631(1.27%). HDV‐positive cases were mainly males (68.2%). Eight cases were cirrhotic (36.4%), 3 (13.6%) had HCC and 7 (31.8%) were HBeAg positive. HDV prevalence is low among chronic hepatitis B patients in the Nile delta, Egypt. Screening for HDV IgG is recommended in CHB patients who had cirrhosis, HCC or HBeAg positive.


The diagnostic value of golgi protien-73 and DICKKOPF-1 in hepatocellular carcinoma
Wafaa Mohammed ElZefzafy, Magda Hussien, Zakia Abu Zahab Mohmmed, and Nashwa Mohammed Abd Elbaky
Informa UK Limited
ABSTRACT Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Early detection of HCC is essential for improved prognosis and long-term survival. Golgi protein-73 (GP73) and Dickkopf-1 (DKK1), can be used as noninvasive biomarkers for early diagnosis of HCC. Aim of the work: measure and assess the clinical utility of Golgi protein-73 and Dickkopf-1 as noninvasive biomarkers for early diagnosis of HCC. This study included 60 patients: 30 patients with HCC, 30 patients with cirrhosis together with 30 healthy controls. There was a highly significant difference in GP73 and DKK1 between all the studied groups. There was a highly significant positive correlation between GP73 and DKK1 and a significant negative correlation between (GP73 and albumin) and (DKK1 and ALT) in group I. GP73, DKK-1 correlated with the number, overall size, and lymph node metastasis. GP73 and DKK1 can serve as diagnostic serologic markers for early HCC as they had high sensitivity and specificity, correlated with the aggressiveness of the tumor superior to AFP. The combined use of GP73, DKK-1, and AFP increased the sensitivity and specificity for the diagnosis of HCC than each one alone.


Diagnostic utility of serum dipeptidyl peptidase (DPP- IV) /CD26 as a serum marker in Egyptian patients with colorectal cancer
Wafaa M. Elzefzafy, Soheir Abd Elrahman, Zakia abuzahab Mohmmed, and Nesreen Atef
Informa UK Limited
ABSTRACT Background Colorectal cancer (CRC) is considered a major cause of morbidity and mortality in Egypt. Colonoscopy is the standard for detection of lesions. The combination of screening methods is effective. Decrease and loss of DPP-IV/CD26 expression and activity are found in microenvironments of specific tumors which are related to impaired immune functions. Aim of the work To study sCD26 as a noninvasive test in Egyptian patients with CRC as well as their correlation to CEA, CA 19–9 & other -biochemical parameters and determine the possibility to use it as a diagnostic tool for CRC. Patients and methods This study included 40 patients divided into two groups: group I: comprised 20 patients with CRC, group II: comprised 20 patients with other colorectal disease together with 20 healthy control. Results There was highly significant decrease in sCD26 in group I in comparison to group II and III. CD26 at cutoff 4.69 mg/mL, its sensitivity was 85% and its specificity was 87.5%. Conclusion CD26 is involved in the pathogenesis of colorectal diseases; sCD26 is diminished in CRC patients suggesting the potential utility of a sCD26 for diagnosis

CONSULTANCY

GIT infecetious disease